Abbott Laboratories (NYSE:ABT) closing share price quoted for February 07, 2019 was $72.74. The -1.02% drop might have been tempting for an investor to sell at this point but in fact that would prove a short-sighted mistake, as sell-side analysts think there is almost 18.23% more gain yet to come for shareholders. The stock enjoyed an overall uptrend of 0.57% from the beginning of 2019. Analysts seemed to set $86 as highest price target on its way to greater gains. The average 12-month price target they expect from the stock is $79.66. This mean price target represents 9.51% upside over its previous closing price. The median price target they presented was $80 for the next 12-months, which suggests a 9.98% upside from current levels. Some analysts have a lowest price target on the stock of $70, which would mean a -3.77% gain in value.
A fresh roundup today notes that ABT stock has added around 23.58% of its value in the past 12 months, suggesting more investors have expressed joy over about in that time period. If we turn to the Street in general, the positives still outweigh the negatives as we can see that Abbott Laboratories (ABT), have a buy (1.9) analyst consensus rating. In the current time, the stock has 18 buy and 2 hold ratings. The stock registered its 52-week high of $74.92 on December 03 and its 52-week low of $55.58 on February 09. Currently, the shares are trading $2.33 above its YTD moving average of $70.41.
Moving on, Abbott Laboratories (ABT) last reported its December 2019 earnings. For brief highlights, it performed well in that quarter, with earnings up 9% year-over-year at $0.81. The company surprised analysts by 0 who were expecting $0.81 per share. Overall, its quarterly revenues jumped by 2% to reach $7.77 billion, while it had reported $7.59 billion in the same period a year ago. To see what investors should really expect from its March 2019 financial results consensus analyst estimates are calling for current quarter earnings per share of $0.61, up from $0.59 in the same quarter a year ago. However, earnings-per-share are expected to see growth of 12.18% in next year. From there, the company believes it can achieve a long-term annual earnings growth rate of 11.06 %. At the other end of the income statement, we have seen revenue of $30.58 billion over the trailing 12 months.
To help you decide whether it’s worth the wait (and the money), Abbott Laboratories (NYSE:ABT) is currently trading at 52.11X the company’s trailing-12-month earnings per share, which represents a premium compared to the sector’s 35.49X and comes in above its industry’s 29.31X. The most popular method for valuing a stock is to study the historic Price-to-Earnings (P/E) ratio using reported earnings for the past 12 months. The EPS number for this stock in the most recent four quarters of earnings stood at $1.4. P/E ratio is so popular because it’s simple, it’s effective, and, tautologically, because everyone uses it.
The 14-day Absolute ATR (Average True Range) on Thursday, February 07 of 2019 shows that the price on average moves $1.6. The average daily volatility is 1.49% over the past week. Low volatility is good for the stock and it means we have calm and confident investors. If you check recent Abbott Laboratories (ABT) volume, you will see that it has changed to 6.82 million shares versus the average daily volume of 7.07 million shares.
When you look at the daily chart for ABT, you will observe the stock held 12.36% gains in the 6-month period and maintains 30.87% distance from its most recent low. The past 5-day performance for the share stays negative at -0.33% but up 2.7% from its three-week moving average. Comparing to 50-day SMA, Abbott Laboratories shares price is now up 3.21%. It also closed 9.24% higher from its 200-day SMA. This is often seen as the last line of defense for long term trends to find support at, else be considered broken and/or in a bear market. The daily chart of the stock more clearly reveals the slide in prices as it closed Thursday with a 1-month performance at 6.5%.
This post was originally published on *this site*